Pierre Fabre and EORTC open a large Phase III clinical study i...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
CASTRES, France and BRUSSELS, May 24, 2022 /PRNewswire-AsiaNet/ -- - First study conducted in the adjuvant setting with a combination of BRAF and MEK inhibitors in high-risk stage II BRAF V600E/K-mutant cutaneous melanoma- A global partnership between EORTC and Pierre Fabre to advance research in melanoma...
Authors: LATEST ASIANET NEWS RELEASES